Finance Watch: Lucky Few Raise Cash While Many Public Biotechs Cut Costs
Restructuring Ongoing As Firms Extend Funding Runways
Public Company Edition: ImmunoGen received the first $75m under a $175m term loan, while Protagonist raised $100m in a follow-on offering, but companies with bankruptcy filings and job cuts outpaced those accessing new capital by a wide margin in late March and early April.
